Shares of Definitive Healthcare Corp. (NASDAQ:DH – Get Free Report) have been assigned an average rating of “Reduce” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $2.4714.
DH has been the topic of a number of research analyst reports. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. Robert W. Baird set a $1.10 price objective on Definitive Healthcare in a report on Friday, May 8th. Bank of America restated an “underperform” rating and issued a $0.70 price objective on shares of Definitive Healthcare in a research report on Monday, June 29th. Finally, Barclays lowered their target price on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a research note on Monday, March 30th.
View Our Latest Stock Analysis on Definitive Healthcare
Institutional Trading of Definitive Healthcare
Definitive Healthcare Price Performance
DH opened at $0.68 on Monday. The firm has a market capitalization of $72.07 million, a P/E ratio of -0.42, a price-to-earnings-growth ratio of 11.02 and a beta of 1.33. Definitive Healthcare has a one year low of $0.62 and a one year high of $4.70. The company has a fifty day moving average price of $0.81 and a 200-day moving average price of $1.24. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75.
Definitive Healthcare (NASDAQ:DH – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Equities research analysts expect that Definitive Healthcare will post 0.04 earnings per share for the current fiscal year.
Definitive Healthcare Company Profile
Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.
The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.
Further Reading
- Five stocks we like better than Definitive Healthcare
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
